Galectin antagonist use in mild cases of SARS-CoV-2; pilot feasibility randomised, open label, controlled trial

Alben Sigamani, Samarth Shetty, Madhavi, Mathu Ruthra, Sudhishma, Anup Chugani, Hana Chen-Walden, ThomasKutty, David Platt
doi: https://doi.org/10.1101/2020.12.03.20238840

Article Information

doi 
https://doi.org/10.1101/2020.12.03.20238840
History 
  • December 9, 2020.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Dr Alben Sigamani*,1,
  2. Dr Samarth Shetty2,
  3. Dr Madhavi2,
  4. Miss Mathu Ruthra3,
  5. Miss Sudhishma3,
  6. Mr Anup Chugani4,
  7. Dr Hana Chen-Walden5,
  8. Mr ThomasKutty, BS-CCP6 and
  9. Dr David Platt7
  1. 1Group Head, Clinical Research, Narayana Health, Bangalore
  2. 2Consultant, Mazumdar Shaw Medical Center, Narayana Health, Bangalore
  3. 3Department of Clinical Research, Narayana Health Bangalore
  4. 4MedGenome Laboratories
  5. 5Medical Officer, Pharmalectin Inc
  6. 6Clinical Perfusionist Baylor Scott& White Health, thomaskutty.alumparambil{at}bswhealth.org
  7. 7Chief Chemist, Pharmalectin Inc
  1. ↵*Corresponding Author, alben.sigamani.dr{at}narayanahealth.org
Back to top
Posted December 09, 2020.
Download PDF
Data/Code
Email
Galectin antagonist use in mild cases of SARS-CoV-2; pilot feasibility randomised, open label, controlled trial
Alben Sigamani, Samarth Shetty, Madhavi, Mathu Ruthra, Sudhishma, Anup Chugani, Hana Chen-Walden, ThomasKutty, David Platt
medRxiv 2020.12.03.20238840; doi: https://doi.org/10.1101/2020.12.03.20238840
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area